Literature DB >> 24657683

Heart failure: TNM-like classification.

Francesco Fedele1, Paolo Severino2, Simone Calcagno2, Massimo Mancone2.   

Abstract

Staging of heart failure represents a major issue in clinical practice. In this setting, the MOGE(S) classification was designed to be similar to the TNM classification used in oncology. Nevertheless, MOGE(S) nosology differs greatly from the key elements of the TNM classification, as well as its simplicity and clinical applicability. In fact, MOGE(S) acronym stands for morphofunctional characteristics (M), organ involvement (O), genetic or familial inheritance pattern (G), etiological information (E), and functional status (S). Recently, a new TNM-like classification for heart failure was proposed. This classification, named HLM, refers to heart damage arising from an initial stage of impaired systolic or diastolic function, without structural injury, to an advanced stage of biventricular dysfunction (H), different stages of lung involvement (L), and malfunction of peripheral organs such as the kidney, liver, and brain (M). HLM classification was influenced by the key elements of TNM staging: simplicity, clinical usefulness, efficacy for planning a therapeutic strategy, and ability to determine patient prognosis. HLM classification seems to be easily applied in the real world and valuable for balancing economic resources with the clinical complexity of patients.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TNM; classification; heart failure

Mesh:

Year:  2014        PMID: 24657683     DOI: 10.1016/j.jacc.2014.02.552

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

Review 1.  Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.

Authors:  Johann Altenberger; Finn Gustafsson; Veli-Pekka Harjola; Kristjan Karason; Detlef Kindgen-Milles; Matti Kivikko; Gabriella Malfatto; Zoltán Papp; John Parissis; Piero Pollesello; Gerhard Pölzl; Carsten Tschöpe
Journal:  J Cardiovasc Pharmacol       Date:  2018-03       Impact factor: 3.105

Review 2.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2020-07       Impact factor: 3.105

Review 3.  Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  Card Fail Rev       Date:  2020-07-08

Review 4.  Prevention of Cardiovascular Disease: Screening for Magnesium Deficiency.

Authors:  Paolo Severino; Lucrezia Netti; Marco Valerio Mariani; Annalisa Maraone; Andrea D'Amato; Rossana Scarpati; Fabio Infusino; Mariateresa Pucci; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Cardiol Res Pract       Date:  2019-05-02       Impact factor: 1.866

Review 5.  Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow.

Authors:  Paolo Severino; Andrea D'Amato; Lucrezia Netti; Mariateresa Pucci; Fabio Infusino; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  J Diabetes Res       Date:  2019-04-04       Impact factor: 4.011

6.  Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.

Authors:  Ryan D Sullivan; Radhika M Mehta; Ranjana Tripathi; Inna P Gladysheva; Guy L Reed
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 7.  Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels.

Authors:  Paolo Severino; Andrea D'Amato; Mariateresa Pucci; Fabio Infusino; Lucia Ilaria Birtolo; Marco Valerio Mariani; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 8.  New Treatment Strategies for Alcohol-Induced Heart Damage.

Authors:  Joaquim Fernández-Solà; Ana Planavila Porta
Journal:  Int J Mol Sci       Date:  2016-09-29       Impact factor: 5.923

9.  From breathless to failure: symptom onset and diagnostic meaning in patients with heart failure-a qualitative study.

Authors:  C J Taylor; F D R Hobbs; T Marshall; F Leyva-Leon; N Gale
Journal:  BMJ Open       Date:  2017-03-10       Impact factor: 2.692

10.  The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure.

Authors:  Markku S Nieminen; Cândida Fonseca; Dulce Brito; Gerhard Wikström
Journal:  Eur Heart J Suppl       Date:  2017-03-08       Impact factor: 1.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.